The CheckMate-067 trial showed a durable response and significantly improved OS with dual checkpoint inhibition with CTLA-4 inhibitor and PD-1 inhibitor in patients with treatment-naïve metastatic melanoma.12,39 This trial led to the FDA approval of the combination therapy of ipilimumab and nivolumab, which became the standard of care for metastatic melanoma in the first-line setting.12,39, , –42 RELATIVITY-047 trial compared dual checkpoint inhibition with relatlimab and nivolumab to nivolumab alone, similar to the comparison made in the CheckMate-067 trial between the two arms. The gene discussed is PDCD1; the disease is metastatic melanoma.